ReproNovo Advances Breakthroughs in Reproductive Medicine and Women’s Health from Copenhagen
ReproNovo Advances Breakthroughs in Reproductive Medicine and Women’s Health from Copenhagen

Case

ReproNovo Advances Breakthroughs in Reproductive Medicine and Women’s Health from Copenhagen

Case

ReproNovo Advances Breakthroughs in Reproductive Medicine and Women’s Health from Copenhagen

When it comes to reproductive medicine and women’s health, Denmark is where science meets societal support. That’s why ReproNovo, founded in 2021 by a team of proven expertise in the reproductive medicine, drug development, and regulatory affairs, chose Denmark as the launchpad for its innovation journey.

When

The company’s mission is clear: close critical gaps in infertility treatment and women’s health worldwide. With proven success in bringing therapies to market, ReproNovo’s team combines years of scientific expertise with a commitment to improving patients’ lives by delivering innovative therapeutic solutions for male and female infertility and pioneering treatment options for conditions like adenomyosis.

Why Denmark?

“Denmark was selected as the location for our R&D hub based on its established expertise in reproductive medicine and access to highly qualified drug development professionals. The country has a strong track record in scientific innovation which provides a favourable atmosphere for advancing research. Finally, we are of course also mindful that Denmark’s policies related to fertility and family support are well aligned with our scientific focus areas.” 

Joan-Carles Arce

MD, PhD, Chief Scientific & Medical Officer

Copenhagen at the core of ReproNovo's innovation

With its primary R&D team based in Copenhagen, ReproNovo benefits from the country’s established life sciences ecosystem, world-class research networks, and progressive approach to health innovation.
ReproNovo is developing first-in-class solutions designed to overcome the limitations of existing treatments in male and female infertility and women’s health. 

  • RPN-001 (leflutrozole): a first-of-its-kind oral compound in development for treatment of infertility in men with low testosterone, an increasingly common condition. Male infertility accounts for up to 50% of infertility cases, yet no approved oral therapies exist today. ReproNovo aims to change that by reducing the burden on women while expanding options for men.
  • RPN-002 (nolasiban): an orally administered oxytocin receptor antagonist with the potential to address adenomyosis, a painful and under-treated condition in women. RPN-002 also holds promise in improving embryo implantation during assisted reproductive technology (ART), an aspect of infertility treatment with no approved drugs to date. https://repronovo.com/ 
    Both candidates underline ReproNovo’s ambition: to turn unmet medical needs into novel therapeutic options.

Denmark: Where innovation meets family values 

Denmark is globally recognised as a frontrunner in reproductive medicine and fertility research. Add to this a digitally advanced healthcare system, strong clinical trial environment, and policies that support families, Denmark provides the perfect ecosystem for companies like ReproNovo to grow innovation that truly matters.

Get in touch

Want to learn more about your R&D opportunities in Denmark?

Invest in Denmark provides free-of-charge confidential and tailor-made solutions for foreign companies looking to set up a new business in Denmark or expand an existing one. Please contact one of our experts here:

Copenhagen

  • Sarina Lohmann

    Title: Special Advisor – Maritime and transport – Analysis & Partnerships

    Area: Copenhagen

    Phone: +4533920423

Berlin

Kolding

Silkeborg

Aarhus

Aalborg

Oslo

London

Paris

Munich

New-York

Toronto

Silicon-Valley

Tokyo

Bangalore

Taipei

Shanghai

Singapore